Cargando…
Management of Locally Advanced or Metastatic Combined Hepatocellular Cholangiocarcinoma
SIMPLE SUMMARY: Combined hepatocellular-cholangiocarcinoma is a rare and aggressive liver tumor that exhibits both hepatocytic and biliary differentiation. In this review we address the recent advances in the genetic and molecular characterization of this tumor and give an overview of possible thera...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913543/ https://www.ncbi.nlm.nih.gov/pubmed/36765942 http://dx.doi.org/10.3390/cancers15030988 |
_version_ | 1784885453099368448 |
---|---|
author | Zhao, Jemmy Stephan-Falkenau, Susann Schuler, Markus Arndt, Börge |
author_facet | Zhao, Jemmy Stephan-Falkenau, Susann Schuler, Markus Arndt, Börge |
author_sort | Zhao, Jemmy |
collection | PubMed |
description | SIMPLE SUMMARY: Combined hepatocellular-cholangiocarcinoma is a rare and aggressive liver tumor that exhibits both hepatocytic and biliary differentiation. In this review we address the recent advances in the genetic and molecular characterization of this tumor and give an overview of possible therapeutic implications and systemic and locoregional treatment approaches of this tumor entity. ABSTRACT: Combined hepatocellular cholangiocarcinoma (cHCC-CC) is a rare primary liver malignancy that comprises features of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Due to the rarity of this tumor, the treatment of choice has not yet been defined. For resectable disease, liver resection is the mainstay treatment. However, most patients relapse or display advanced disease and were not surgical candidates. Although the majority of patients are either primarily or secondarily treated in palliative intent, no guideline recommendations or prospective trial reports exist to allow reliable evaluation of debated treatment options. We review different locoregional or medical treatment options for advanced combined hepatocellular cholangiocarcinoma (cHCC-CC) in the neoadjuvant, adjuvant, or palliative setting and discuss the possibility of predictive biomarker-guided therapeutic options. |
format | Online Article Text |
id | pubmed-9913543 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99135432023-02-11 Management of Locally Advanced or Metastatic Combined Hepatocellular Cholangiocarcinoma Zhao, Jemmy Stephan-Falkenau, Susann Schuler, Markus Arndt, Börge Cancers (Basel) Review SIMPLE SUMMARY: Combined hepatocellular-cholangiocarcinoma is a rare and aggressive liver tumor that exhibits both hepatocytic and biliary differentiation. In this review we address the recent advances in the genetic and molecular characterization of this tumor and give an overview of possible therapeutic implications and systemic and locoregional treatment approaches of this tumor entity. ABSTRACT: Combined hepatocellular cholangiocarcinoma (cHCC-CC) is a rare primary liver malignancy that comprises features of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Due to the rarity of this tumor, the treatment of choice has not yet been defined. For resectable disease, liver resection is the mainstay treatment. However, most patients relapse or display advanced disease and were not surgical candidates. Although the majority of patients are either primarily or secondarily treated in palliative intent, no guideline recommendations or prospective trial reports exist to allow reliable evaluation of debated treatment options. We review different locoregional or medical treatment options for advanced combined hepatocellular cholangiocarcinoma (cHCC-CC) in the neoadjuvant, adjuvant, or palliative setting and discuss the possibility of predictive biomarker-guided therapeutic options. MDPI 2023-02-03 /pmc/articles/PMC9913543/ /pubmed/36765942 http://dx.doi.org/10.3390/cancers15030988 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Zhao, Jemmy Stephan-Falkenau, Susann Schuler, Markus Arndt, Börge Management of Locally Advanced or Metastatic Combined Hepatocellular Cholangiocarcinoma |
title | Management of Locally Advanced or Metastatic Combined Hepatocellular Cholangiocarcinoma |
title_full | Management of Locally Advanced or Metastatic Combined Hepatocellular Cholangiocarcinoma |
title_fullStr | Management of Locally Advanced or Metastatic Combined Hepatocellular Cholangiocarcinoma |
title_full_unstemmed | Management of Locally Advanced or Metastatic Combined Hepatocellular Cholangiocarcinoma |
title_short | Management of Locally Advanced or Metastatic Combined Hepatocellular Cholangiocarcinoma |
title_sort | management of locally advanced or metastatic combined hepatocellular cholangiocarcinoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913543/ https://www.ncbi.nlm.nih.gov/pubmed/36765942 http://dx.doi.org/10.3390/cancers15030988 |
work_keys_str_mv | AT zhaojemmy managementoflocallyadvancedormetastaticcombinedhepatocellularcholangiocarcinoma AT stephanfalkenaususann managementoflocallyadvancedormetastaticcombinedhepatocellularcholangiocarcinoma AT schulermarkus managementoflocallyadvancedormetastaticcombinedhepatocellularcholangiocarcinoma AT arndtborge managementoflocallyadvancedormetastaticcombinedhepatocellularcholangiocarcinoma |